New Imaging Modalities In The Evaluation Of Patients Wit

评估患者机智的新成像方式

• 批准号: 6659606
• 负责人: Karel Pacak
• 金额: --
• 依托单位: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6659606
• 关键词: Cushing's syndrome; adrenocorticotropic hormone; clinical research; cortisol; deoxyglucose; diagnosis design /evaluation; endocrine disorder diagnosis; human subject; human tissue; hypercortisolism; positron emission tomography

Between 10% and 20% of patients with hypercortisolism (Cushing?s syndrome) have ectopic production of adrenocorticotropin hormone (ACTH). In approximately 50% of these patients, the source of ACTH cannot be found despite very detailed and extensive examination including imaging studies such as computed tomography scanning, magnetic resonance imaging, and octreotide scan using the conventional low dose of 111-indium pentetreotide ([111In-DTPA-D-Phe]-pentetreotide). This protocol tests whether [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning or use of a higher dose of [111In-DTPA-D-Phe]-pentetreotide can be used to localize successfully the source of ectopic ACTH production. To date fluorodeoxyglucose PET scanning successfully identified the tumor in less than 30% of patients.Low dose Octreoscan successfully localized the tumor in more than 40% of patients. High dose Octreoscan successfully localized the tumor in only one patient out of seven patients in whom low dose Octreoscan was negative. This study continues to find out whether fluorodeoxyglucose PET scanning and high dose Octreoscan compared to conventional imaging modalities can provide additional imaging strategies for patients with ectopic Cushing's syndrome.

在10％到20％的高皮层溶酶（库什综合症）患者中，异位产生肾上腺皮质激素激素（ACTH）。在这些患者中，大约有50％的人使用非常详细且进行了广泛的检查，包括计算机断层扫描，磁共振成像和Ocrotreotide扫描，但使用传统的低剂量五粒五托赛肽（[[111in-dtpa-d-d-phe] -pentphe] -pentetretide）。该协议测试[18F] - 氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）扫描还是使用较高剂量的[111in-DTPA-D-PHE] - 五替肽可用于成功地将其局部定位于位置ACTH产生的来源。迄今为止，氟脱氧葡萄糖PET扫描成功地鉴定出不到30％的患者的肿瘤。低剂量的Octreoscan成功地将肿瘤定位在40％以上的患者中。高剂量的尾巴成功将肿瘤定位在七名患者中的一名患者中，其中低剂量的尾treoscan为阴性。这项研究继续找出与常规成像方式相比，氟脱氧葡萄糖PET扫描和高剂量的眼镜是否可以为异位库欣综合征患者提供其他成像策略。